Research advances in gene therapy approaches for the treatment of amyotrophic lateral sclerosis

Cellular and Molecular Life Sciences

Volumn 69, Issue 10, 2012, Pages 1641-1650

  Nizzardo, Monica ^a   Simone, Chiara ^a   Falcone, Marianna ^a   Riboldi, Giulietta ^a   Rizzo, Federica ^a   Magri, Francesca ^a   Bresolin, Nereo ^a   Comi, Giacomo P ^a   Corti, Stefania ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Adeno associated vectors; Amyotrophic lateral sclerosis; Gene therapy; RNA interference

Indexed keywords

ANGIOGENIN; ANTISENSE OLIGONUCLEOTIDE; FAS ANTIGEN; FOLLISTATIN; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; GLUTAMATE RECEPTOR 3; NEUROTROPHIN RECEPTOR P75; PARVOVIRUS VECTOR; PROTEIN BCL 2; SMALL INTERFERING RNA; SOMATOMEDIN C; SUPEROXIDE DISMUTASE; VASCULOTROPIN;

AMYOTROPHIC LATERAL SCLEROSIS; ANTISENSE THERAPY; ANTISENSE VECTOR; ASTROCYTE; CELL DIFFERENTIATION; CELL PROLIFERATION; GENE; GENE EXPRESSION; GENE SILENCING; HETEROZYGOSITY; HUMAN; MEDICAL RESEARCH; NEUROPROTECTION; NONHUMAN; PROMOTER REGION; REVIEW; RNA DEGRADATION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; SMN GENE; SOD1 GENE; TROPISM; VIRAL GENE DELIVERY SYSTEM;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; DEPENDOVIRUS; DISEASE MODELS, ANIMAL; GENE THERAPY; GENETIC VECTORS; MICE; NEUROPROTECTIVE AGENTS; RATS; RNA INTERFERENCE; SUPEROXIDE DISMUTASE;

ADENO-ASSOCIATED VIRUS; ANIMALIA;

EID: 84863558665     PISSN: 1420682X     EISSN: 14209071     Source Type: Journal    
DOI: 10.1007/s00018-011-0881-5     Document Type: Review

References (87)

1. Cleveland DW (1999) From Charcot to SOD1: mechanisms of selective motor neuron death in ALS. Neuron 24:515-520
2. Kiernan MC, Vucic S, Cheah BC, Turner MR, Eisen A, Hardi-man O, Burrell JR, Zoing MC (2011) Amyotrophic lateral sclerosis. Lancet 377(9769):942-955
3. Chio A, Mora G, Calvo A, Mazzini L, Bottacchi E, Mutani R (2009) Epidemiology of ALS in Italy: a 10-year prospective population-based study. Neurology 72:725-731
4. Alonso A, Logroscino G, Jick SS, Hernan MA (2009) Incidence and lifetime risk of motor neuron disease in the United Kingdom: a population-based study. Eur J Neurol 16:745-751
5. Rosen DR, Siddique T, Patterson D, Figlewicz DA, Sapp P, Hentati A, Donaldson D, Goto J, O'Regan JP, Deng HX et al (1993) Mutations in Cu/Zn superoxide dismutase gene are asso-ciated with familial amyotrophic lateral sclerosis. Nature 362:59-62 (Pubitemid 23087289)
6. Traub R, Mitsumoto H, Rowland LP (2011) Research advances in amyotrophic lateral sclerosis, 2009 to 2010. Curr Neurol Neu-rosci Rep 11:67-77
7. Daoud H, Valdmanis PN, Kabashi E, Dion P, Dupré N, Camu W, Meininger V, Rouleau GA (2009) Contribution of TARDBP mutations to sporadic amyotrophic lateral sclerosis. J Med Genet 46:112-114
8. Belzil VV, Valdmanis PN, Dion PA, Daoud H, Kabashi E, Noreau A, Gauthier J, S2D team, Hince P, Desjarlais A, Bouchard JP, Lacomblez L, Salachas F, Pradat PF, Camu W, Meininger V, Dupré N, Rouleau GA (2009) Mutations in FUS cause FALS and SALS in French and French Canadian popula-tions. Neurology 73:1176-1179
9. Maruyama H, Morino H, Ito H, Izumi Y, Kato H, Watanabe Y, Kinoshita Y, Kamada M, Nodera H, Suzuki H, Komure O, Matsuura S, Kobatake K, Morimoto N, Abe K, Suzuki N, Aoki M, Kawata A, Hirai T, Kato T, Ogasawara K, Hirano A, Takumi T, Kusaka H, Hagiwara K, Kaji R, Kawakami H (2010) Muta-tions of optineurin in amyotrophic lateral sclerosis. Nature 465:223-226
10. Orlacchio A, Babalini C, Borreca A, Patrono C, Massa R, Bas-aran S, Munhoz RP, Rogaeva EA, St George-Hyslop PH, Bernardi G, Kawarai T (2010) SPATACSIN mutations cause autosomal recessive juvenile amyotrophic lateral sclerosis. Brain 133:591-598
11. Lefebvre S, Bürglen L, Reboullet S, Clermont O, Burlet P, Viollet L, Benichou B, Cruaud C, Millasseau P, Zeviani M et al (1995) Identification and characterization of a spinal muscular atrophy-determining gene. Cell 80(1):155-165
12. Foust KD, Nurre E, Montgomery CL, Hernandez A, Chan CM, Kaspar BK (2009) Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes. Nat Biotechnol 27:59-65
13. Passini MA, Bu J, Roskelley EM, Richards AM, Sardi SP, O'Riordan CR, Klinger KW, Shihabuddin LS, Cheng SH (2010) CNS-targeted gene therapy improves survival and motor function in a mouse model of spinal muscular atrophy. J Clin Invest 120:1253-1264
14. Dominguez E, Marais T, Chatauret N, Benkhelifa-Ziyyat S, Duque S, Ravassard P, Carcenac R, Astord S, de Moura AP, Voit T, Barkats M (2011) Intravenous scAAV9 delivery of a codon-optimized SMN1 sequence rescues SMA mice. Hum Mol Genet 20:681-693
15. Valori CF, Ning K, Wyles M, Mead RJ, Grierson AJ, Shaw PJ, Azzouz M (2010) Systemic delivery ofscAAV9 expressing SMN prolongs survival in a model of spinal muscular atrophy. Sci Transl Med 2:35-42
16. Mello CC, Conte D Jr (2004) Revealing the world of RNA interference. Nature 431:338-342 (Pubitemid 39265673)
17. Dreyer JL (2011) Lentiviral vector-mediated gene transfer and RNA silencing technology in neuronal dysfunctions. Mol Bio-technol 47:169-187 Review
18. Crooke ST (2004) Progress in antisense technology. Annu Rev Med 55:61-95 (Pubitemid 38316716)
19. Aartsma-Rus A, van Ommen GJ (2010) Progress in therapeutic antisense applications for neuromuscular disorders. Eur J Hum Genet 18:146-153
20. Hua Y, Vickers TA, Okunola HL, Bennett CF, Krainer AR (2008) Antisense masking of an hnRNP A1/A2 intronic splicing silencer corrects SMN2 splicing in transgenic mice. Am J Hum Genet 82:834-848
21. Krol J, Fiszer A, Mykowska A, Sobczak K, de Mezer M, Krzyzosiak WJ (2007) Ribonuclease dicer cleaves triplet repeat hairpins into shorter repeats that silence specific targets. Mol Cell 25:575-586 (Pubitemid 46274449)
22. van Deutekom JC, Janson AA, Ginjaar IB, Frankhuizen WS, Aartsma-Rus A, Bremmer-Bout M, den Dunnen JT, Koop K, van der Kooi AJ, Goemans NM, de Kimpe SJ, Ekhart PF, Venneker EH, Platenburg GJ, Verschuuren JJ, van Ommen GJ (2007) Local dystrophin restoration with antisense oligonucleotide PRO051. N Engl J Med 357:2677-2686
23. Wheeler TM, Lueck JD, Swanson MS, Dirksen RT, Thornton CA (2007) Correction of ClC-1 splicing eliminates chloride chan-nelopathy and myotonia in mouse models of myotonic dystrophy. J Clin Invest 117:3952-3957 (Pubitemid 350224104)
24. Ralph GS, Radcliffe PA, Day DM, Carthy JM, Leroux MA, Lee DC, Wong LF, Bilsland LG, Greensmith L, Kingsman SM, Mitrophanous KA, Mazarakis ND, Azzouz M (2005) Silencing mutant SOD1 using RNAi protects against neurodegeneration and extends survival in an ALS model. Nat Med 11:429-433 (Pubitemid 40562334)
25. Raoul C, Abbas-Terki T, Bensadoun JC, Guillot S, Haase G, Szulc J, Henderson CE, Aebischer P (2005) Lentiviral-mediated silencing of SOD1 through RNA interference retards disease onset and progression in a mouse model of ALS. Nat Med 11:423-428 (Pubitemid 40562333)
26. Saito Y, Yokota T, Mitani T, Ito K, Anzai M, Miyagishi M, Taira K, Mizusawa H (2005) Transgenic small interfering RNA halts amyotrophic lateral sclerosis in a mouse model. J Biol Chem 280:42826-42830 (Pubitemid 43049244)
27. Miller TM, Kim SH, Yamanaka K, Hester M, Umapathi P, Arnson H, Rizo L, Mendell JR, Gage FH, Cleveland DW, Kaspar BK (2006) Gene transfer demonstrates that muscle is not a pri-mary target for non-cell-autonomous toxicity in familial amyotrophic lateral sclerosis. Proc Natl Acad Sci USA 103:19546-19551 (Pubitemid 46026068)
28. Miller VM, Paulson HL, Gonzalez-Alegre P (2005) RNA inter-ference in neuroscience: progress and challenges. Cell Mol Neurobiol 25:1195-1207 (Pubitemid 43037033)
29. Xia X, Zhou H, Huang Y, Xu Z (2006) Allele-specific RNAi selectively silences mutant SOD1 and achieves significant ther-apeutic benefit in vivo. Neurobiol Dis 23:578-586 (Pubitemid 44234094)
30. Towne C, Raoul C, Schneider BL, Aebischer P (2008) Systemic AAV6 delivery mediating RNA interference against SOD1: neuromuscular transduction does not alter disease progression in fALS mice. Mol Ther 16:1018-1025 (Pubitemid 351737065)
31. Wang H, Ghosh A, Baigude H, Yang CS, Qiu L, Xia X, Zhou H, Rana TM, Xu Z (2008) Therapeutic gene silencing delivered by a chemically modified small interfering RNA against mutant SOD1 slows amyotrophic lateral sclerosis progression. J Biol Chem 283:15845-15852
32. Rizvanov AA, Mukhamedyarov MA, Palotás A, Islamov RR (2009) Retrogradely transported siRNA silences human mutant SOD1 in spinal cord motor neurons. Exp Brain Res 195:1-4
33. Wu R, Wang H, Xia X, Zhou H, Liu C, Castro M, Xu Z (2009) Nerve injection of viral vectors efficiently transfers transgenes into motor neurons and delivers RNAi therapy against ALS. Antioxid Redox Signal 11:1523-1534
34. Kubodera T, Yamada H, Anzai M, Ohira S, Yokota S, Hirai Y, Mochizuki H, Shimada T, Mitani T, Mizusawa H, Yokota T (2011) In vivo application of an RNAi strategy for the selective suppression of a mutant allele. Hum Gene Ther 22:27-34
35. Kubodera T, Yokota T, Ishikawa K, Mizusawa H (2005) New RNAi strategy for selective suppression of a mutant allele in polyglutamine disease. Oligonucleotides 15:298-302 (Pubitemid 43108226)
36. Harper SQ (2009) Progress and challenges in RNA interference therapy for Huntington disease. Arch Neurol 66:933-938
37. Towne C, Setola V, Schneider BL, Aebischer P (2011) Neuro-protection by gene therapy targeting mutant SOD1 in individual pools of motor neurons does not translate into therapeutic benefit in fALS mice. Mol Ther 19:274-283
38. Daya S, Berns KI (2008) Gene therapy using adeno-associated virus vectors. Clin Microbiol Rev 21:583-593
39. Mandel RJ, Manfredsson FP, Foust KD, Rising A, Reimsnider S, Nash K, Burger C (2006) Recombinant adeno-associated viral vectors as therapeutic agents to treat neurological disorders. Mol Ther 13:463-483 (Pubitemid 43257615)
40. Smith RA, Miller TM, Yamanaka K, Monia BP, Condon TP, Hung G, Lobsiger CS, Ward CM, McAlonis-Downes M, Wei H, Wancewicz EV, Bennett CF, Cleveland DW (2006) Antisense oligonucleotide therapy for neurodegenerative disease. J Clin Invest 116:2290-2296 (Pubitemid 44162339)
41. Turner BJ, Cheah IK, Macfarlane KJ, Lopes EC, Petratos S, Langford SJ, Cheema SS (2003) Antisense peptide nucleic acid-mediated knockdown of the p75 neurotrophin receptor delays motor neuron disease in mutant SOD1 transgenic mice. J Neuro-chem 87(3):752-763 (Pubitemid 37310640)
42. Rembach A, Turner BJ, Bruce S, Cheah IK, Scott RL, Lopes EC, Zagami CJ, Beart PM, Cheung NS, Langford SJ, Cheema SS (2004) Antisense peptide nucleic acid targeting GluR3 delays disease onset and progression in the SOD1 G93A mouse model of familial ALS. J Neurosci Res 77(4):573-582 (Pubitemid 39007009)
43. Locatelli F, Corti S, Papadimitriou D, Fortunato F, Del Bo R, Donadoni C, Nizzardo M, Nardini M, Salani S, Ghezzi S, Strazzer S, Bresolin N, Comi GP (2007) Fas small interfering RNA reduces motoneuron death in amyotrophic lateral sclerosis mice. Ann Neurol 62:81-92 (Pubitemid 47235283)
44. Azzouz M (2006) Gene therapy for ALS: progress and prospects. Biochim Biophys Acta 1762:1122-1127 (Pubitemid 44750578)
45. Davidson BL, Breakefield XO (2003) Viral vectors for gene delivery to the nervous system. Nat Rev Neurosci 4:353-364 (Pubitemid 37280174)
46. Bessis N, GarciaCozar FJ, Boissier MC (2004) Immune responses to gene therapy vectors: influence on vector function and effector mechanisms. Gene Ther 11:S10-S17 (Pubitemid 39359442)
47. Haberman RP, Samulski RJ, McCown TJ (2003) Attenuation of seizures and neuronal death by adeno-associated virus vector galanin expression and secretion. Nat Med 9:1076-1080 (Pubitemid 37021789)
48. Guy J, Qi X, Muzyczka N, Hauswirth WW (1999) Reporter expression persists 1 year after adeno-associated virus-mediated gene transfer to the optic nerve. Arch Ophthalmol 117:929-937 (Pubitemid 29330781)
49. Wu Z, Asokan A, Samulski RJ (2006) Adeno-associated virus serotypes: vector toolkit for human gene therapy. Mol Ther 14:316-327 (Pubitemid 44184972)
50. McCown TJ (2005) Adeno-associated virus (AAV) vectors in the CNS. Curr Gene Ther 5:333-338 (Pubitemid 40895017)
51. Mueller C, Flotte TR (2008) Clinical gene therapy using recom-binant adeno-associated virus vectors. Gene Ther 15:858-863 (Pubitemid 351712619)
52. Burger C, Gorbatyuk OS, Velardo MJ et al (2004) Recombinant AAV viral vectors pseudotyped with viral capsids from serotypes 1, 2, and 5 display differential efficiency and cell tropism after delivery to different regions of the central nervous system. Mol Ther 10:302-317 (Pubitemid 39117875)
53. Bartlett JS, Samulski RJ, McCown TJ (1998) Selective and rapid uptake of adeno-associated virus type 2 in brain. Hum Gene Ther 9:1181-1186 (Pubitemid 28269004)
54. McFarland NR, Lee JS, Hyman BT, McLean PJ (2009) Com-parison of transduction efficiency of recombinant AAV serotypes 1, 2, 5, and 8 in the rat nigrostriatal system. J Neurochem 109:838-845
55. Liu G, Martins IH, Chiorini JA, Davidson BL (2005) Adeno-associated virus type 4 (AAV4) targets ependyma and astrocytes in the subventricular zone and RMS. Gene Ther 12:1503-1508 (Pubitemid 41508675)
56. Tenenbaum L, Chtarto A, Lehtonen E, Velu T, Brotchi J, Levi-vier M (2004) Recombinant AAV-mediated gene delivery to the central nervous system. J Gene Med 6:S212-S222 (Pubitemid 40228030)
57. Davidson BL, Stein CS, Heth JA, Martins I, Kotin RM, Derksen TA, Zabner J, Ghodsi A, Chiorini JA (2000) Recombinant adeno-associated virus type 2, 4, and 5 vectors: transduction of variant cell types and regions in the mammalian central nervous system. Proc Natl Acad Sci USA 97:3428-3432 (Pubitemid 30183319)
58. Hutson TH, Verhaagen J, Yáñez-Muñoz RJ, Moon LD (2011) Corticospinal tract transduction: a comparison of seven adeno-associated viral vector serotypes and a non-integrating lentiviral vector. Gene Ther. 2011 May 12
59. Duque S, Joussemet B, Riviere C, Marais T, Dubreil L, Douar AM, Fyfe J, Moullier P, Colle MA, Barkats M (2009) Intravenous administration of self-complementary AAV9 enables transgene delivery to adult motor neurons. Mol Ther 17:1187-1196
60. Foust KD, Nurre E, Montgomery CL, Hernandez A, Chan CM, Kaspar BK (2009) Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes. Nat Biotechnol 27:59-65
61. Broekman ML, Comer LA, Hyman BT, Sena-Esteves M (2006) Adeno-associated virus vectors serotyped with AAV8 capsid are more efficient than AAV-1 or -2 serotypes for widespread gene delivery to the neonatal mouse brain. Neuroscience 138:501-510 (Pubitemid 43255560)
62. Lawlor PA, Bland RJ, Mouravlev A, Young D, During MJ (2009) Efficient gene delivery and selective transduction of glial cells in the mammalian brain by AAV serotypes isolated from nonhuman primates. Mol Ther 17:1692-1702
63. Burger C, Gorbatyuk OS, Velardo MJ, Peden CS, Williams P, Zolotukhin S, Reier PJ, Mandel RJ, Muzyczka N (2004) Recombinant AAV viral vectors pseudotyped with viral capsids from serotypes 1, 2, and 5 display differential efficiency and cell tropism after delivery to different regions of the central nervous system. Mol Ther 10:302-317 (Pubitemid 39117875)
64. Maheshri N, Koerber JT, Kaspar BK, Schaffer DV (2006) Directed evolution of adeno-associated virus yields enhanced gene delivery vectors. Nat Biotechnol 24:198-204 (Pubitemid 43221704)
65. Li W, Asokan A, Wu Z, Van Dyke T, DiPrimio N, Johnson JS, Govindaswamy L, Agbandje-McKenna M, Lechtle S, Redmond DE Jr, McCown TJ, Petermann KB, Sharpless NE, Samulski RJ (2008) Engineering and selection of shuffled AAV genomes: a new strategy for producing targeted biological nanoparticles. Mol Ther 16:1252-1260 (Pubitemid 351866056)
66. Shevtsova Z, Malik JM, Michel U, Bähr M, Kügler S (2005) Promoters and serotypes: targeting of adeno-associated virus vectors for gene transfer in the rat central nervous system in vitro and in vivo. Exp Physiol 90:53-59
67. Federici T, Boulis NM (2006) Gene-based treatment of motor neuron diseases. Muscle Nerve 33:302-323
68. Zavalishin IA, Bochkov NP, Suslina ZA, Zakharova MN, Tarantul VZ, Naroditskiy BS, Suponeva NA, Illarioshkin SN, Shmarov MM, Logunov DY, Tutyhina IL, Verkhovskaya LV, Sedova ES, Vasiliev AV, Brylev LV, Ginzburg AL (2008) Gene therapy of amyotrophic lateral sclerosis. Bull Exp Biol Med 145:483-486
69. Moroianu J, Riordan JF (1994) Nuclear translocation of angio-genin in proliferating endothelial cells is essential to its angiogenic activity. Proc Natl Acad Sci USA 91:1677-1681 (Pubitemid 24080268)
70. Kishimoto K, Liu S, Tsuji T, Olson KA, Hu GF (2005) Endog-enous angiogenin in endothelial cells is a general requirement for cell proliferation and angiogenesis. Oncogene 24:445-456 (Pubitemid 40188592)
71. Tsuji T, Sun Y, Kishimoto K, Olson KA, Liu S, Hirukawa S, Hu GF (2005) Angiogenin is translocated to the nucleus of HeLa cells and is involved in ribosomal RNA transcription and cell proliferation. Cancer Res 65:1352-1360 (Pubitemid 40270162)
72. Greenway MJ, Andersen PM, Russ C, Ennis S, Cashman S, Donaghy C, Patterson V, Swingler R, Kieran D, Prehn J, Morrison KE, Green A, Acharya KR, Brown RH Jr, Hardiman O (2006) ANG mutations segregate with familial and 'sporadic' amyotrophic lateral sclerosis. Nat Genet 38:411-413
73. Crabtree B, Thiyagarajan N, Prior SH, Wilson P, Iyer S, Ferns T, Shapiro R, Brew K, Subramanian V, Acharya KR (2007) Char-acterization of human angiogenin variants implicated in amyotrophic lateral sclerosis. Biochemistry 46:11810-11818 (Pubitemid 47623749)
74. Wu D, Yu W, Kishikawa H, Folkerth RD, Iafrate AJ, Shen Y, Xin W, Sims K, Hu GF (2007) Angiogenin loss-of-function mutations in amyotrophic lateral sclerosis. Ann Neurol 62:609-617
75. Kieran D, Sebastia J, Greenway MJ, King MA, Connaughton D, Concannon CG, Fenner B, Hardiman O, Prehn JH (2008) Control of motoneuron survival by angiogenin. J Neurosci 28(52): 14056-14061
76. Neff NT, Prevette D, Houenou LJ, Lewis ME, Glicksman MA, Yin QW, Oppenheim RW (1993) Insulin-like growth factors: putative muscle-derived trophic agents that promote motoneuron survival. J Neurobiol 24:1578-1588 (Pubitemid 23340328)
77. Li L, Oppenheim RW, Lei M, Houenou LJ (1994) Neurotrophic agents prevent motoneuron death following sciatic nerve section in the neonatal mouse. J Neurobiol 25:759-766 (Pubitemid 24191245)
78. Yuan Q, Wu W, So KF, Cheung AL, Prevette DM, Oppenheim RW (2000) Effects of neurotrophic factors on motoneuron sur-vival following axonal injury in newborn rats. Neuroreport 11:2237-2241 (Pubitemid 30485569)
79. Lepore AC, Haenggeli C, Gasmi M, Bishop KM, Bartus RT, Maragakis NJ, Rothstein JD (2007) Intraparenchymal spinal cord delivery of adeno-associated virus IGF-1 is protective in the SOD1G93A model ofALS. Brain Res 1185:256-265 (Pubitemid 350166301)
80. Dodge JC, Haidet AM, Yang W, Passini MA, Hester M, Clarke J, Roskelley EM, Treleaven CM, Rizo L, Martin H, Kim SH, Kaspar R, Taksir TV, Griffiths DA, Cheng SH, Shihabuddin LS, Kaspar BK (2008) Delivery of AAV-IGF-1 to the CNS extends survival in ALS mice through modification of aberrant glial cell activity. Mol Ther 16:1056-1064 (Pubitemid 351737070)
81. Franz CK, Federici T, Yang J, Backus C, Oh SS, Teng Q, Carlton E, Bishop KM, Gasmi M, Bartus RT, Feldman EL, Boulis NM (2009) Intraspinal cord delivery of IGF-I mediated by adeno-associated virus 2 is neuroprotective in a rat model of familial ALS. Neurobiol Dis 33:473-481
82. Dodge JC, Treleaven CM, Fidler JA, Hester M, Haidet A, Handy C, Rao M, Eagle A, Matthews JC, Taksir TV, Cheng SH, Shi-habuddin LS, Kaspar BK (2010) AAV4-mediated expression of IGF-1 and VEGF within cellular components of the ventricular system improves survival outcome in familial ALS mice. Mol Ther 8:2075-2084
83. Petruska JC, Kitay B, Boyce VS, Kaspar BK, Pearse DD, Gage FH, Mendell LM (2010) Intramuscular AAV delivery of NT-3 alters synaptic transmission to motoneurons in adult rats. Eur J Neurosci 32:997-1005
84. Welte K, Platzer E, Gabrilove JL, Lu L, Levi E, Polivka A et al (1985) Purification to apparent homogeneity and biochemical characterization of human pluripotent hematopoietic colony-stimulating factor. Haematol Blood Transfus 29:398-401
85. Pitzer C, Krüger C, Plaas C, Kirsch F, Dittgen T, Müller R et al (2008) Granulocytecolony stimulating factor improves outcome in a mouse model of amyotrophic lateral sclerosis. Brain 131:3335-3347
86. Henriques A, Pitzer C, Dittgen T, Klugmann M, Dupuis L, Schneider A (2011) CNS-targeted viral delivery of G-CSF in an animal model for ALS: improved efficacy and preservation of the neuromuscular unit Mol Ther 19(2):284-292
87. Lim S, Airavaara M, Harvey BK (2010) Viral vectors for neu-rotrophic factor delivery: a gene therapy approach for neurodegenerative diseases of the CNS. Pharmacol Res 61:14-26